Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.
Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Gastroenterology. 2014 Apr;146(4):1084-96. doi: 10.1053/j.gastro.2013.12.041. Epub 2014 Jan 11.
BACKGROUND & AIMS: Although there are a few highly penetrant mutations that are linked directly to cancer initiation, more less-penetrant susceptibility alleles have been associated with cancer risk and progression. We used RNA sequence analysis to search for genetic variations associated with pathogenesis of hepatocellular carcinoma (HCC).
We analyzed 400 paired HCC and adjacent nontumor tissues, along with clinical information, from patients who underwent surgery at Sun Yat-Sen University in Guangzhou, China. Total RNA was extracted from tissues and sequenced, and variations with allele imbalance were identified. Effects of variants on cell functions were investigated in HCC cell lines and tumor xenografts in mice. Variants were associated with patient outcomes.
We found a high proportion of allele imbalance in genes related to cellular stress. A nucleotide variation in the Oxidative Stress-Induced Growth Inhibitor 1 (OSGIN1) gene (nt 1494: G-A) resulted in an amino acid substitution (codon 438: Arg-His). The variant form of OSGIN1 was specifically retained in the tumor tissues. Functional assays showed that the common form of OSGIN1 functioned as a tumor suppressor, sensitizing HCC cells to chemotherapeutic agents by inducing apoptosis. However, the variant form of OSGIN1 was less effective. It appeared to affect the translocation of OSGIN1 from the nucleus to mitochondria, which is important for its apoptotic function. The expression pattern and localization of OSGIN1 was altered in HCC specimens, compared with adjacent liver tissue. Levels of OSGIN1 messenger RNA were reduced in 24.7% of HCC specimens, and down-regulation was associated with shorter overall and disease-free survival times of patients. Patients with the OSGIN1 1494A variant had the shortest mean survival time (32.68 mo) among patient subgroups, and their tumor samples had the lowest apoptotic index.
We identified OSGIN1 as a tumor suppressor that is down-regulated or altered in human HCCs. Variants of OSGIN1 detected in HCC samples reduce apoptosis and are associated with shorter survival times of patients.
虽然有一些与癌症发生直接相关的高度外显突变,但更多低外显度的易感性等位基因与癌症风险和进展相关。我们使用 RNA 序列分析来寻找与肝细胞癌 (HCC) 发病机制相关的遗传变异。
我们分析了来自中国广州中山大学接受手术治疗的 400 对 HCC 及相邻非肿瘤组织,以及临床资料。从组织中提取总 RNA 并进行测序,鉴定等位基因失衡的变异。在 HCC 细胞系和小鼠肿瘤异种移植中研究变异对细胞功能的影响。分析变异与患者结局的关系。
我们发现与细胞应激相关的基因中存在很高比例的等位基因失衡。氧化应激诱导生长抑制剂 1 (OSGIN1) 基因中的核苷酸变异 (nt1494: G-A) 导致氨基酸取代 (密码子 438: Arg-His)。OSGIN1 的变异形式特异性保留在肿瘤组织中。功能测定显示,常见形式的 OSGIN1 作为肿瘤抑制因子发挥作用,通过诱导细胞凋亡使 HCC 细胞对化疗药物敏感。然而,变异形式的 OSGIN1 效果较差。它似乎影响 OSGIN1 从核到线粒体的易位,这对其凋亡功能很重要。与相邻肝组织相比,OSGIN1 在 HCC 标本中的表达模式和定位发生了改变。在 24.7%的 HCC 标本中,OSGIN1 信使 RNA 水平降低,下调与患者总生存期和无病生存期缩短有关。在患者亚组中,携带 OSGIN1 1494A 变异的患者平均生存时间最短 (32.68 个月),其肿瘤样本的凋亡指数最低。
我们确定 OSGIN1 是一种在人类 HCC 中下调或改变的肿瘤抑制因子。在 HCC 样本中检测到的 OSGIN1 变异降低了细胞凋亡,并与患者生存时间缩短相关。